Log in to your Inderes Free account to see all free content on this page.
Stayble Therapeutics
0.398
SEK
+3.11 %
STABL
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Be the first to follow this company
+3.11%
-33.67%
-39.24%
+46.32%
+31.35%
+26.35%
-93.73%
-
-94.68%
Stayble Therapeutics operates in the pharmaceutical industry. The company specializes in research and development of injection treatments for pain caused by herniated discs. The drug candidates are developed and based on a proprietary technological platform. Most operations are found in the Nordic market and the company has its headquarters in Gothenburg.
Read moreMarket cap
17.4M SEK
Turnover
54.36K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
25.2.
2025
Annual report '24
ShowingAll content types
Stayble Therapeutics' STA363 receives positive phase 1b results
Stayble Therapeutics: Stayble's CEO to BioStock: "We are looking forward to new study results in 2024"
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio